3. A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin monotherapy in high-risk subjects presenting with acute coronary syndrome

4. IMPROVE-IT: Enrollment and Study Period

5. IMPROVE-IT: Study Goals

6. PROVE-IT Trial

7. National Cholesterol Education Program Adult Treatment Panel III Guidelines

8. LDL Hypothesis: Is Lowering LDL Enough, or Does the Agent Matter?

9. ENHANCE: Ezetimibe/Simvastatin in Familial Hypercholesterolemia

10. Challenges Faced During IMPROVE-IT

11. Determinants of Atherosclerosis

12. CTT Meta-Analysis of 26 Trials: More Intensive Lowering of LDL-C

13. IMPROVE-IT: Lower LDL-C Level With Ezetimibe/Simvastatin Combination

14. IMPROVE-IT: Ezetimibe/Simvastatin Reduces Risk of Cardiovascular Events

15. Selection of End Points in Statin Trials

16. IMPROVE-IT: Subgroup Analysis 7-year Event Rates

17. No Increased Risk of Cancer With Ezetimibe

19. SHARP: Ezetimibe/Simvastatin Reduces Risk of Atherosclerotic Events in CKD

20. Statin Intolerance

21. IMPROVE-IT: Safety Data

22. Ezetimibe Target: NPC1L1-A Sterol Transporter

23. Genetic Targets in LDL-C Lowering: PCSK9

24. Early LDL-C Level Predicts Cardiovascular Disease

25. Genetic Targets in LDL-C Lowering APOB

26. Recommendations: Match Intensity of Therapy to Absolute Risk

27. JPPP: Low-Dose Aspirin in Elderly Japanese Patients With CV Risk Factors

28. Longer-Term Dual Antiplatelet Therapy Reduces Risk of MACCE

29. TNT Trial: Intensive Statin Therapy Reduces Risk of Cardiovascular Events

30. Primary Prevention

31. CCTA Does Not Reduce Cardiovascular Risk in High-Risk Patients With DM

32. Abbreviations

33. Abbreviations (cont)

34. References

35. References (cont)

36. References (cont)

37. References (cont)

38. References (cont)

39. References (cont)

40. References (cont)